Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 11/20 | 0.67 |
| ▸ | GPR34 | Q9UPC5 | 7/20 | 0.67 |
| ▸ | GPR174 | Q9BXC1 | 7/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | DGKA | P23743 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3506307 | 1.00 | P2RY10 (0.67) | P2RY10GPR34GPR174MAPTLMNA | |
| SCHEMBL27805088 | 1.00 | P2RY10 (0.67) | P2RY10GPR34GPR174MAPTLMNA | |
| SCHEMBL27805090 | 1.00 | P2RY10 (0.67) | P2RY10GPR34GPR174MAPTLMNA | |
| SCHEMBL360370 | 1.00 | P2RY10 (0.67) | P2RY10GPR34GPR174MAPTLMNA | |
| SCHEMBL2578612 | 1.00 | P2RY10 (0.67) | P2RY10GPR34GPR174MAPTLMNA | |
| SCHEMBL27890891 | 1.00 | P2RY10 (0.67) | P2RY10GPR34GPR174MAPTLMNA | |
| SCHEMBL3506305 | 1.00 | P2RY10 (0.67) | P2RY10GPR34GPR174MAPTLMNA | |
| SCHEMBL7797430 | 1.00 | P2RY10 (0.67) | P2RY10GPR34GPR174MAPTLMNA | |
| SCHEMBL7794681 | 0.91 | P2RY10 (0.71) | P2RY10GPR34GPR174DGKA | |
| SCHEMBL7794685 | 0.91 | P2RY10 (0.71) | P2RY10GPR34GPR174DGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX SA (FR) | 2014-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | P2RY10 13/4885GPR34 473/4885GPR174 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.